SMLR

Semler Scientific Inc. operates in the healthcare sector, within the medical devices and diagnostic technologies subsegment, with its shares traded on Nasdaq. The company’s founding is associated with Douglas Murphy-Chutorian and other professionals with backgrounds in biomedical engineering, medical technology, and healthcare management.

The company was established in a private setting, without direct government involvement. Its initial motivations were related to the development of technology-driven solutions for the noninvasive assessment of cardiovascular conditions, with an emphasis on clinical efficiency, scalability, and support for medical decision-making.

Its core products and services consist of proprietary diagnostic systems based on integrated software and hardware, primarily focused on the detection and evaluation of peripheral vascular disease. These solutions leverage physiological measurement technologies and data analytics applied within clinical environments.

The company’s market presence is predominantly national, with a primary focus on the United States. Its solutions are used by healthcare providers, clinics, hospitals, primary care organizations, and payers operating across multiple U.S. states.

Key market factors include population aging, the rising prevalence of cardiovascular diseases, growing demand for early-stage diagnostics, the digitalization of clinical workflows, changes in healthcare reimbursement models, and competition from other medical technology and diagnostic solution providers.

The company’s operating scale is characterized by a concentrated base of institutional healthcare clients, licensing and service agreements, and operations focused on high value-added solutions. Its activities do not involve large-scale manufacturing of complex medical equipment.

Its operating structure is organized around technology development, clinical validation, technical support, commercialization, and regulatory management. The corporate headquarters is located in the United States, with centralized operations and strategic partnerships for distribution and implementation.

The primary trading ticker is SMLR, listed on Nasdaq, representing the common shares of Semler Scientific Inc. in the U.S. equity market.

History and foundation

The company was founded in 2007 in the United States, with the establishment of Semler Scientific Inc. as a business focused on the development of noninvasive medical diagnostic technologies, during a period of increasing integration between healthcare and technology.

During its early years of operation, key challenges included clinical validation of its solutions, obtaining regulatory approvals, adapting products to the requirements of the U.S. healthcare system, and building credibility among medical professionals and institutions.

Expansion and growth were driven by the continuous enhancement of its technology platforms, the expansion of its customer base within the primary care segment, and the consolidation of recurring revenue models based on licensing and services.

Historical milestones include the completion of the initial public offering (IPO) in 2014, with the listing of its shares on Nasdaq, as well as the launch and ongoing evolution of proprietary solutions focused on vascular diagnostics and integration with digital clinical workflows.

Between 2020 and 2024, relevant developments included adaptation to operational changes in the healthcare sector, strategic adjustments to commercial models, continued technological evolution of its platforms, fluctuations in share performance, and regulatory and macroeconomic impacts on the medical devices and healthcare technology market.

Additional Information

The Company Semler Scientific Inc (United States), is listed on Nasdaq with a market value of $ 304.95 Millions, having an equity of $ 459.75 Millions.

The Company is listedthe in the sector of Others and categorized in industry of Others.

In the last 12 months the Company had a revenue of $ 36.96 Millions, which generated a profit in the amount of $ 48.34 Millions.

As for its main indicators, the Company has a P/E ratio of 6.31, a P/BV ratio of 0.66 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker SMLR.